Vistide

Company description

Gilead Sciences is an independent biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has demonstrated its capability to develop and commercialize products throughout the world over the last 15 years. Gilead has successfully marketed its anti-infective product line consisting of AmBisome[R] (amphotericin B) liposome for injection, Viread[R] (tenofovir disoproxil fumarate), Hepsera[TM] (adefovir dipivoxil), Vistide[R] (cidofovir injection), and DaunoXome[R] (liposomal daunorubicin). Liposomal products include AmBisome, which is approved in 46 countries for treating life-threatening fungal infections, and DaunoXome, which is approved in more than 20 countries for the treatment of AIDS-related Kaposi's Sarcoma.

Gilead continues to leverage its expertise and proprietary technology in the field of liposomal drug delivery through its own internal development of product candidates as well as through collaborations with third parties for formulation, development, and manufacturing services relevant to their needs. Gilead's facilities in San Dimas, California are dedicated to liposome research and development and to pilot through commercial scale production of both liquid and lyophilized presentations.

Technology description

At Gilead, we have the proven scientific and regulatory expertise in liposomal drug development to maximize the success of your therapeutic compounds. Gilead's Liposome Technology Group offers an in-depth understanding of the subtleties of liposome formulation and a proven track record in designing liposomes that are amenable to scale-up, regulatory approval, and commercialization. While Gilead has successfully commercialized anti-infective and anti-cancer liposomal products, it has expertise in formulating active agents from a wide range of other therapeutic categories. Whether drug solubilization or therapeutic index improvement is the goal in formulating a compound, Gilead's SOLVE[SM] and VECTOR[SM] systems provide formulation options. Gilead has partnered with companies requiring assistance at all stages of the product development cycle from initial formulation development through commercial-scale manufacturing. For more information on Gilead's Liposome Technology Group, please visit www.gilead.com or call our business development department at 909.394.4179.

Gilead Sciences, Inc.

650 Cliffside Dr.

San Dimas CA 91773

TELEPHONE

909.394.4179

FAX

909.592.8530

WEB SITE

www.gilead.com

E-MAIL

cskenes@gilead.com

Circle/eINFO 85

COPYRIGHT 2003 Advanstar Communications, Inc.
COPYRIGHT 2004 Gale Group